AAV6 VP1 + VP2 + VP3, recombinant proteins, set
Western blot analysis of recombinant AAV2 VP proteins (Cat. No. 72001), recombinant AAV5 VP proteins (Cat. No. 72005), recombinant AAV6 VP proteins (Cat. No. 72006), recombinant AAV8 VP proteins (Cat. No. 72008) and recombiant AAV9 VP proteins (Cat. No. 72009) with B1 antibody (Cat. No. 690058). Western blot analysis was performed on the precise molar ratio of 1:1:10 (13.5 ng VP1:11 ng VP2:100 ng VP3) combined in one lane. The PVDF membrane was blocked with 5% milk in PBST for 1 h at RT.
The primary antibody anti-AAV VP1/VP2/VP3, B1 (Cat. No. 690058) was diluted in blocking buffer (antibody concentration 500 ng/ml) and incubated for 1 h at RT. The secondary antibody anti-mouse IgG HRP was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Undiluited = 100 µg/ml, pre-diluted = 10 µg/ml
Western blot analysis of recombinant AAV2 VP proteins (Cat. No. 72001), recombinant AAV5 VP proteins (Cat. No. 72005), recombinant AAV6 VP proteins (Cat. No. 72006), recombinant AAV8 VP proteins (Cat. No. 72008) and recombiant AAV9 VP proteins (Cat. No. 72009) with B1 antibody (Cat. No. 690058). Western blot analysis was performed on the precise molar ratio of 1:1:10 (13.5 ng VP1:11 ng VP2:100 ng VP3) combined in one lane. The PVDF membrane was blocked with 5% milk in PBST for 1 h at RT.
The primary antibody anti-AAV VP1/VP2/VP3, B1 (Cat. No. 690058) was diluted in blocking buffer (antibody concentration 500 ng/ml) and incubated for 1 h at RT. The secondary antibody anti-mouse IgG HRP was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Undiluited = 100 µg/ml, pre-diluted = 10 µg/ml
• Useful for ratio analysis
• Precise molar concentration
• Suitable for WB, dot blot, SDS PAGE
Included products:
Product description
| Quantity | 10 µg each protein |
|---|---|
| Application | Dot blot, SDS PAGE, WB |
| Purification | Ni-NTA chromatography |
| Storage | -80°C |
| Intended use | Research use only |
| Concentration | 100 µg/ml (VP1: 1.19 µM, VP2: 1.45 µM, VP3: 1.61 µM) |
| Formulation | Liquid, 6 M urea in PBS |
| Source | Escherichia coli |
| Molecular weight | VP1: 83.6 kDa, VP2: 68.5 kDa, VP3: 61.8 kDa (calculated Mw from aa sequence) |
| Purity | > 95% (determined by SDS PAGE) |
| Product description | N-terminal His-tagged (MGSSHHHHHHSSGLVPRGSH) recombinant AAV6 capsid proteins VP1 + VP2 + VP3 |
Applications
| Tested applications | Tested dilutions |
|---|---|
| Dot Blot | 100 ng, depending on primary antibody and detection method |
| SDS PAGE | 1 µg |
| Western Blot (WB) | 5-20 ng, depending on primary antibody and detection method |
Background
The AAV capsid consists of three capsid proteins, i.e. VP1, VP2 and VP3, which differ in their N-terminus and encapsulate the genomic ssDNA. In native virus particles, the three proteins form subunits with a ratio of 1:1:10 (VP1:VP2:VP3), in a total number of 60 subunits per capsid.
This set of recombinant AAV6 VP1, VP2 and VP3 can be used to create a mixture with the precise molar ratio of 1:1:10 to compare the protein composition of the viral capsid in your sample by protein detection methods, e.g. western blot.
All three recombinant AAV6 capsid proteins are available as set (Cat. No. 72006) or as individual proteins (Cat. No. 640836, 640837, 640838).
Downloads
Customer Reviews
Login
Related Products
